Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quartz Bio Supports Debiopharm Group Precision Medicine Bioinformatics

Published: Friday, July 05, 2013
Last Updated: Friday, July 05, 2013
Bookmark and Share
Debiopharm Group™ have signed a one-year collaboration agreement with Quartz Bio.

Debiopharm Group™ has announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery.

Under the research framework, Quartz Bio will apply its leading expertise in bioinformatics to support Debiopharm translational projects in terms of computational analyses and biomarker discovery.

Projects are expected to range from preclinical Next-Generation Sequencing to clinical biomarker data analyses.

“We are delighted to collaborate with Debiopharm,” said Dr. Jerome Wojcik, CEO of Quartz Bio. “Debiopharm’s pioneering biomarker projects are a unique opportunity for Quartz Bio to contribute to the implementation of Precision Medicine, thus demonstrating that bioinformatics science can bring substantial benefits to patients”.

“We look forward to collaborating with Quartz Bio,” commented Dr. Hiroaki Tanaka, Director of Personalized Medicine at Debiopharm.

Dr. Tanaka continued, “Their longstanding clinical bioinformatics experience made them an ideal partner to support our biomarker projects in our clinical trials and extract from data the relevant information required for personalized therapy development”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cenix BioScience and Debiopharm Sign Research Agreement
Both Companies collaborate to identify predictive biomarkers.
Thursday, May 23, 2013
Debiopharm, Immunexpress and Biocartis Announce Collaboration
Collaboration to advance development of SeptiCyte® Triage for managing sepsis.
Wednesday, December 26, 2012
Debiopharm Group™ and Biocartis embark on a Partnership Aiming at Enhancing Personalized Medicine
- Debiopharm Group™ , a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
Thursday, April 08, 2010
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl® to Further Help Prostate Cancer Patients
Debiopharm Group announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl® (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Thursday, September 25, 2008
Debiopharm and EPFL Sign Research Project Agreement
The project agreement will identify inhibitors of signalling pathways controlling cell fate for cancer treatment.
Monday, September 15, 2008
Debiopharm Signs Canadian Partner for Sanvar®
Debiopharm signs license and supply agreement with Medical Futures Inc. for the Canadian distribution rights to SANVAR® IR.
Friday, February 22, 2008
Scientific News
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!